



Q & M DENTAL GROUP (SINGAPORE) LIMITED

(Company Registration Number 200800507R)

(Incorporated in the Republic of Singapore)

APPOINTMENT OF AZION HEALTHCARE SDN BHD AS EXCLUSIVE DISTRIBUTOR FOR ACU-CORONA[®] 3.0 CORONAVIRUS TEST KITS IN MEXICO

- 1 The board of directors (the "**Board**" or "**Directors**") of Q & M Dental Group (Singapore) Limited ("**Q & M**" or the "**Company**", and together with its subsidiaries, the "**Group**") is pleased to announce that the Group's 51% subsidiary, Acumen Diagnostics Pte. Ltd. along with Acumen Research Laboratories Pte. Ltd. had entered into an exclusive distribution agreement dated 14 July 2020 (the executed copy of which was received by the Company on 22 July 2020) ("**Agreement**") with Azion Healthcare Sdn Bhd ("**Azion**").
- 2 Pursuant to the terms of the Agreement, Azion has been appointed as the exclusive buyer and distributor of Acu-Corona[®] 3.0 (Singapore Health Sciences Authority, Provisional Authorisation MDPA2020-19) COVID-19 reverse transcription polymerase chain reaction (RT-PCR) test kits (the "**Products**") in the United Mexican States also, known as Mexico ("**Territory**") for a duration of six (6) months from the date of the Agreement ("**Initial Term**"). The duration of the Agreement can be automatically renewed in six (6) month blocks provided that Azion purchases, subject to all necessary validation and approval of the Product by all relevant Mexican authorities ("**Regulatory Approvals**"), five (5) million tests within three (3) months of the date of obtaining Regulatory Approvals.
- 3 Azion is a company incorporated in Malaysia and primarily engaged in the business of research and development, manufacturing, commercialisation, marketing, sale of and investment in, medical and pharmaceutical solutions around the globe.
- 4 Shareholders and potential investors should note that the import and sale of the Products in the Territory is subject to obtaining Regulatory Approvals. There is no certainty on when such Regulatory Approvals will be obtained.
- 5 Save through their respective shareholdings in the Company (if any), the Company is not aware of any of its Directors or substantial shareholders having any interest, direct or indirect, in the Agreement.
- 6 Shareholders and potential investors should note that policies in relation to diagnosis and/or detection of the COVID-19 virus and/or antibodies in various jurisdictions may change in response to developments in the COVID-19 situation which is evolving rapidly. Shareholders and other investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or

other professional advisers if they are in doubt about the actions that they should take.

By Order of the Board

Q & M Dental Group (Singapore) Limited

Vitters Sim
Chief Financial Officer
23 July 2020

For more information, please contact:

Chief Financial Officer

Vitters Sim
Tel: 6705 9888
Email: vitters@qnm.sg